114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
一种用于增强乳腺癌抗肿瘤治疗的细胞膜包被金纳米粒子药物递送系统
Authors Zhang H, Liu J, Wang Y, Cai A, Tang Y, Zhao J , Yuan H
Received 7 August 2025
Accepted for publication 14 December 2025
Published 22 December 2025 Volume 2025:20 Pages 15479—15491
DOI https://doi.org/10.2147/IJN.S559080
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Krishna Nune
Haiguang Zhang,1 Junchuang Liu,2 Yinli Wang,2 Aiqin Cai,3 Yitian Tang,4 Jinjin Zhao,4 Hongchang Yuan2
1Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 2Department of Clinical Pharmacy, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 3Department of Infection Management, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 4Department of Clinical Lab, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China
Correspondence: Jinjin Zhao, Email hdzhaojinjin@163.com Hongchang Yuan, Email 116597551@qq.com
Purpose: Doxorubicin (DOX) is a first-line chemotherapeutic agent widely recognized for its efficacy in inhibiting tumor growth. However, its clinical utility is limited by systemic toxicity, adverse side effects, and the emergence of multidrug resistance. To address these challenges, we developed a cell membrane-coated nanodrug delivery system in which DOX is loaded onto gold nanoparticles (AuNPs) via electrostatic adsorption, with the cell membrane acted as a biomimetic targeting component to improve therapeutic outcomes and reduce off-target toxicity.
Methods: The successful construction of M@DOX@AuNPs was confirmed by UV-Vis absorption spectroscopy and transmission electron microscope. Antitumor effects were evaluated through both in vitro and in vivo experiments. Biological safety was evaluated via histopathological staining and blood biochemical analysis.
Results: M@DOX@AuNPs demonstrated favorable physical stability and exhibited time-dependent drug release profiles. Cellular uptake studies revealed that M@DOX@AuNPs were internalized more efficiently in 4T1 and MDA-MB-231 cells compared to free DOX or DOX@AuNPs. Moreover, M@DOX@AuNPs significantly inhibited tumor cell viability and induced apoptosis in vitro, whereas free AuNPs or cell membranes alone showed no detrimental effects on tumor cell viability. In a mouse tumor model, M@DOX@AuNPs exhibited pronounced anti-tumor efficacy without inducing structure damage to major organs or causing significant alterations in blood cell counts and serum biochemical markers.
Conclusion: These findings indicate that M@DOX@AuNPs represent a promising targeted chemotherapeutic agent for improved tumor therapy.
Keywords: doxorubicin, gold nanoparticles, cell membrane, nano-drug delivery system, tumor therapy
1Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 2Department of Clinical Pharmacy, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 3Department of Infection Management, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China; 4Department of Clinical Lab, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, People’s Republic of China
Correspondence: Jinjin Zhao, Email hdzhaojinjin@163.com Hongchang Yuan, Email 116597551@qq.com
Purpose: Doxorubicin (DOX) is a first-line chemotherapeutic agent widely recognized for its efficacy in inhibiting tumor growth. However, its clinical utility is limited by systemic toxicity, adverse side effects, and the emergence of multidrug resistance. To address these challenges, we developed a cell membrane-coated nanodrug delivery system in which DOX is loaded onto gold nanoparticles (AuNPs) via electrostatic adsorption, with the cell membrane acted as a biomimetic targeting component to improve therapeutic outcomes and reduce off-target toxicity.
Methods: The successful construction of M@DOX@AuNPs was confirmed by UV-Vis absorption spectroscopy and transmission electron microscope. Antitumor effects were evaluated through both in vitro and in vivo experiments. Biological safety was evaluated via histopathological staining and blood biochemical analysis.
Results: M@DOX@AuNPs demonstrated favorable physical stability and exhibited time-dependent drug release profiles. Cellular uptake studies revealed that M@DOX@AuNPs were internalized more efficiently in 4T1 and MDA-MB-231 cells compared to free DOX or DOX@AuNPs. Moreover, M@DOX@AuNPs significantly inhibited tumor cell viability and induced apoptosis in vitro, whereas free AuNPs or cell membranes alone showed no detrimental effects on tumor cell viability. In a mouse tumor model, M@DOX@AuNPs exhibited pronounced anti-tumor efficacy without inducing structure damage to major organs or causing significant alterations in blood cell counts and serum biochemical markers.
Conclusion: These findings indicate that M@DOX@AuNPs represent a promising targeted chemotherapeutic agent for improved tumor therapy.
Keywords: doxorubicin, gold nanoparticles, cell membrane, nano-drug delivery system, tumor therapy